

M100-S23

Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement

SAMPLE

This document provides updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards Mo2-A11, Mo7-A9, and M11-A8.

An informational supplement for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Administrative Procedures.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@cls.org

Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement

Abstract

The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)-approved standards: M02-A11—*Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Eleventh Edition*; M07-A9—*Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition*; and M11-A8—*Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—Eighth Edition*. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria.

Clinicians depend heavily on information from the clinical microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results requires that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents.

The tabular information presented here represents the most current information for drug selection, interpretation, and quality control using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the most current edition appear in boldface type.)

Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement*. CLSI document M100-S23 (ISBN 1-56238-865-7 [Print]; ISBN 1-56238-866-5 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2013.

The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A11—*Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Eleventh Edition*; M07-A9—*Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition*; and M11-A8—*Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—Eighth Edition* are followed.

Copyright ©2013 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement*. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.

Twenty-Third Informational Supplement
January 2013

Sixteenth Informational Supplement
January 2006

Twenty-Second Informational Supplement
January 2012

Fifteenth Informational Supplement
January 2005

Twenty-First Informational Supplement
January 2011

Fourteenth Informational Supplement
January 2004

Twentieth Informational Supplement (Update)
June 2010

Thirteenth Informational Supplement
January 2003

Twentieth Informational Supplement
January 2010

Twelfth Informational Supplement
January 2002

Nineteenth Informational Supplement
January 2009

Eleventh Informational Supplement
January 2001

Eighteenth Informational Supplement
January 2008

Tenth Informational Supplement
January 2000

Seventeenth Informational Supplement
January 2007

Ninth Informational Supplement
January 1999

ISBN 1-56238-865-7 (Print)
ISBN 1-56238-866-5 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Contents

| | |
|--|----|
| Abstract..... | 1 |
| Committee Membership..... | 5 |
| Summary of Major Changes in This Document | 15 |
| Summary of CLSI Processes for Establishing Interpretive Criteria and Quality Control Ranges..... | 21 |
| CLSI Reference Methods vs Commercial Methods and CLSI vs FDA Interpretive Criteria (Breakpoints)..... | 22 |
| Subcommittee on Antimicrobial Susceptibility Testing Mission Statement | 24 |
| Instructions for Use of Tables..... | 25 |
| Table 1A. Suggested Groupings of Antimicrobial Agents With FDA Clinical Indications That Should Be Considered for Routine Testing and Reporting on Nonfastidious Organisms by Clinical Microbiology Laboratories in the United States | 34 |
| Table 1B. Suggested Groupings of Antimicrobial Agents With FDA Clinical Indications That Should Be Considered for Routine Testing and Reporting on Fastidious Organisms by Clinical Microbiology Laboratories in the United States | 38 |
| Table 1C. Suggested Groupings of Antimicrobial Agents That Should Be Considered for Routine Testing and Reporting on Anaerobic Organisms..... | 42 |
| Tables 2A–2J. Zone Diameter and Minimal Inhibitory Concentration (MIC) Interpretive Standards for: | |
| 2A. <i>Enterobacteriaceae</i> | 44 |
| Table 2A Supplemental Table 1. Screening and Confirmatory Tests for ESBLs in <i>Klebsiella pneumoniae</i> , <i>Klebsiella oxytoca</i> , <i>Escherichia coli</i> , and <i>Proteus mirabilis</i> for Use With Table 2A..... | 50 |
| Table 2A Supplemental Table 2. Confirmatory Test for Suspected Carbapenemase Production in <i>Enterobacteriaceae</i> for Use With Table 2A..... | 53 |
| Table 2A Supplemental Table 3. Screening and Confirmatory Tests for Suspected Carbapenemase Production in <i>Enterobacteriaceae</i> When Using “Old” Interpretive Criteria for Carbapenems (for Use With Table 2A in M100-S20 [January 2010])..... | 57 |
| 2B-1. <i>Pseudomonas aeruginosa</i> | 62 |
| 2B-2. <i>Acinetobacter</i> spp..... | 66 |
| 2B-3. <i>Burkholderia cepacia</i> | 68 |
| 2B-4. <i>Stenotrophomonas maltophilia</i> | 69 |
| 2B-5. Other Non- <i>Enterobacteriaceae</i> | 70 |
| 2C. <i>Staphylococcus</i> spp. | 72 |

Contents (Continued)

| | |
|---|-----|
| Table 2C Supplemental Table 1. Screening Tests for β -Lactamase Production, Oxacillin Resistance, and <i>mecA</i> -Mediated Oxacillin Resistance Using Cefoxitin in the <i>Staphylococcus aureus</i> Group for Use With Table 2C..... | 80 |
| Table 2C Supplemental Table 2. Screening Tests for Vancomycin MIC ≥ 8 μ g/mL, Inducible Clindamycin Resistance, and High-Level Mupirocin Resistance in the <i>Staphylococcus aureus</i> Group for Use With Table 2C..... | 84 |
| Table 2C Supplemental Table 3. Screening Tests for β -Lactamase Production, <i>mecA</i> -Mediated Oxacillin Resistance Using Cefoxitin, and Inducible Clindamycin Resistance in Coagulase-Negative Staphylococci (except <i>Staphylococcus lugdunensis</i>) for Use With Table 2C..... | 87 |
| 2D. <i>Enterococcus</i> spp. | 90 |
| Table 2D Supplemental Table 1. Screening Tests for High-Level Aminoglycoside Resistance (HLAR) and Vancomycin MIC ≥ 8 μ g/mL in <i>Enterococcus</i> spp. for Use With Table 2D | 94 |
| 2E. <i>Haemophilus influenzae</i> and <i>Haemophilus parainfluenzae</i> | 96 |
| 2F. <i>Neisseria gonorrhoeae</i> | 100 |
| 2G. <i>Streptococcus pneumoniae</i> | 104 |
| Table 2G Supplemental Table 1. Screening Test for Inducible Clindamycin Resistance in <i>Streptococcus pneumoniae</i> for Use With Table 2G | 109 |
| 2H-1. <i>Streptococcus</i> spp. β -Hemolytic Group..... | 112 |
| Table 2H-1 Supplemental Table 1. Screening Test for Inducible Clindamycin Resistance in <i>Streptococcus</i> spp., β -Hemolytic Group for Use With Table 2H-1 | 116 |
| 2H-2. <i>Streptococcus</i> spp. Viridans Group | 118 |
| 2I. <i>Neisseria meningitidis</i> | 122 |
| 2J. Anaerobes..... | 126 |
| Table 3A. Disk Diffusion: Quality Control Ranges for Nonfastidious Organisms (Unsupplemented Mueller-Hinton Medium)..... | 130 |
| Table 3B. Disk Diffusion: Quality Control Ranges for Fastidious Organisms..... | 134 |
| Table 3C. Disk Diffusion: Reference Guide to Quality Control Frequency | 136 |
| Table 3D. Disk Diffusion: Troubleshooting Guide..... | 140 |
| Table 4A. MIC: Quality Control Ranges for Nonfastidious Organisms (Unsupplemented Mueller-Hinton Medium [Cation-Adjusted if Broth])..... | 142 |
| Table 4B. MIC: Quality Control Ranges for Fastidious Organisms (Broth Dilution Methods) | 146 |

Contents (Continued)

| | |
|--|-----|
| Table 4C. MIC: Quality Control Ranges for <i>Neisseria gonorrhoeae</i> (Agar Dilution Method)..... | 148 |
| Table 4D. MIC: Quality Control Ranges for Anaerobes (Agar Dilution Method)..... | 149 |
| Table 4E. MIC: Quality Control Ranges for Anaerobes (Broth Microdilution Method)..... | 150 |
| Table 4F. MIC: Reference Guide to Quality Control Frequency..... | 152 |
| Table 4G. MIC: Troubleshooting Guide..... | 156 |
| Table 5A. Solvents and Diluents for Preparation of Stock Solutions of Antimicrobial Agents..... | 160 |
| Table 5B. Preparation of Stock Solutions for Antimicrobial Agents Provided With Activity Expressed as Units. | 164 |
| Table 5C. Preparation of Solutions and Media Containing Combinations of Antimicrobial Agents..... | 166 |
| Table 6A. Scheme for Preparing Dilutions of Antimicrobial Agents to Be Used in Agar Dilution Susceptibility Tests..... | 168 |
| Table 7A. Scheme for Preparing Dilutions of Antimicrobial Agents to Be Used in Broth Dilution Susceptibility Tests..... | 170 |
| Table 7B. Scheme for Preparing Dilutions of Water-Insoluble Antimicrobial Agents to Be Used in Broth Dilution Susceptibility Tests..... | 171 |
| Appendix A. Suggestions for Confirmation of Resistant (R), Intermediate (I), or Nonsusceptible (NS) Antimicrobial Susceptibility Test Results and Organism Identification..... | 172 |
| Appendix B. Intrinsic Resistance..... | 176 |
| Appendix C. Quality Control Strains for Antimicrobial Susceptibility Tests..... | 182 |
| Appendix D. Cumulative Antimicrobial Susceptibility Report for <i>Bacteroides fragilis</i> Group Organisms..... | 186 |
| Appendix E. Cumulative Antimicrobial Susceptibility Report for Anaerobic Organisms Other Than <i>Bacteroides fragilis</i> Group..... | 187 |
| Glossary I (Part 1). β -Lactams: Class and Subclass Designation and Generic Name | 190 |
| Glossary I (Part 2). Non- β -Lactams: Class and Subclass Designation and Generic Name..... | 191 |
| Glossary II. Abbreviations/Routes of Administration/Drug Class for Antimicrobial Agents Listed in M100-S23 | 192 |
| Glossary III. List of Identical Abbreviations Used for More Than One Antimicrobial Agent in US Diagnostic Products | 195 |
| Informational – User Questions and Subcommittee Responses | 196 |

Contents (Continued)

| | |
|--|-----|
| The Quality Management System Approach | 198 |
| Related CLSI Reference Materials | 199 |

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: +610.688.0100; Fax: +610.688.0700; E-mail: customerservice@clsi.org; Website: www.clsi.org.

The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are as follows:

| | | | |
|-----------------------|--------------------------|------------------------|--------------------------------|
| Organization | Personnel | Process Management | Nonconforming Event Management |
| Customer Focus | Purchasing and Inventory | Documents and Records | Assessments |
| Facilities and Safety | Equipment | Information Management | Continual Improvement |

M100-S23 does not address any of the QSEs. For a description of the documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

| Organization | Customer Focus | Facilities and Safety | Personnel | Purchasing and Inventory | Equipment | Process Management | Documents and Records | Information Management | Nonconforming Event Management | Assessments | Continual Improvement |
|--------------|----------------|-----------------------|-----------|--------------------------|-----------|--|-----------------------|------------------------|--------------------------------|-------------|-----------------------|
| | | | | | | EP23 M02 M07 M11 M23 M39 M45 | M07 | | | | |

Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination and their respective sequential subprocesses. All laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

M100-S23 addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

| Preexamination | | | | Examination | | | Postexamination | |
|----------------------|-------------------|------------------|---------------------------|---------------------------|--------------------------------|--------------------------------|---------------------------------|-------------------|
| Examination ordering | Sample collection | Sample transport | Sample receipt/processing | Examination | Results review and follow-up | Interpretation | Results reporting and archiving | Sample management |
| | | | | EP23 M02 M07 M11 | X EP23 M02 M07 M11 | X EP23 M02 M07 M11 | X M02 M07 M11 | |

Related CLSI Reference Materials*

- EP23-A™** **Laboratory Quality Control Based on Risk Management; Approved Guideline (2011).** This document provides guidance based on risk management for laboratories to develop quality control plans tailored to the particular combination of measuring system, laboratory setting, and clinical application of the test.
- M02-A11** **Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Eleventh Edition (2012).** This document contains the current Clinical and Laboratory Standards Institute–recommended methods for disk susceptibility testing, criteria for quality control testing, and updated tables for interpretive zone diameters.
- M07-A9** **Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition (2012).** This document addresses reference methods for the determination of minimal inhibitory concentrations of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution.
- M11-A8** **Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—Eighth Edition (2012).** This standard provides reference methods for the determination of minimal inhibitory concentrations of anaerobic bacteria by agar dilution and broth microdilution.
- M23-A3** **Development of *In Vitro* Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline—Third Edition (2008).** This document addresses the required and recommended data needed for the selection of appropriate interpretive criteria and quality control ranges for antimicrobial agents.
- M39-A3** **Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline—Third Edition (2009).** This document describes methods for recording and analysis of antimicrobial susceptibility test data, consisting of cumulative and ongoing summaries of susceptibility patterns of clinically significant microorganisms.
- M45-A2** **Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition (2010).** This document provides guidance to clinical microbiology laboratories for standardized susceptibility testing of infrequently isolated or fastidious bacteria that are not presently included in CLSI documents M02 or M07. The tabular information in this document presents the most current information for drug selection, interpretation, and quality control for the infrequently isolated or fastidious bacterial pathogens included in this guideline.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we're adding initiatives to bring even more value to our members and customers.



Shop Our Online Products

Including eM100, the interactive searchable database for drug selection, interpretation, and quality control procedures within M100-S23.



Visit the CLSI U Education Center

Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.



Shop Our Online Products

Including eCLIPSE Ultimate Access™, CLSI's cloud-based, online portal that makes it easy to access our standards and guidelines—*anytime, anywhere.*



Find Membership Opportunities

See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.

For more information, visit www.clsi.org today.

SAMPLE



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

950 West Valley Road, Suite 2500, Wayne, PA 19087 USA

P: 610.688.0100 Toll Free (US): 877.447.1888 F: 610.688.0700

E: customerservice@clsi.org www.clsi.org

PRINT ISBN 1-56238-865-7

ELECTRONIC ISBN 1-56238-866-5